Bretylium is a class II antiarrhythmic agent belonging to the guanidinium family, primarily indicated for the emergency treatment of life-threatening ventricular arrhythmias, including ventricular fibrillation… Read more
Bretylium is a class II antiarrhythmic agent belonging to the guanidinium family, primarily indicated for the emergency treatment of life-threatening ventricular arrhythmias, including ventricular fibrillation and pulseless ventricular tachycardia. By blocking the release of noradrenaline from peripheral sympathetic nerve terminals, this medication helps stabilize cardiac rhythm in critical care protocols. The Bretylium category encompasses high-quality reference standards of the active pharmaceutical ingredient, alongside its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical and clinical laboratories rely on these essential materials for rigorous impurity profiling, method validation, and ongoing quality control testing. Utilizing these specialized compounds ensures the accuracy and reliability of analytical procedures required to verify the purity and stability of Bretylium formulations throughout the drug development and manufacturing lifecycle.